Integrative Characterization on the function of COPD GWAS gene, HHIP

COPD GWAS 基因 HHIP 功能的综合表征

基本信息

  • 批准号:
    10379283
  • 负责人:
  • 金额:
    $ 65.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-05 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

Chronic obstructive pulmonary disease (COPD), ranks as the third leading cause of death in the U.S. It is also strongly influenced by cigarette smoke (CS) and genetic predisposition. HHIP, encoding Hedgehog interacting protein, has consistently been associated with the susceptibility to COPD including airway remodeling and emphysema. However, the molecular mechanism underlying this association remains incompletely understood. Our published work has demonstrated that Hhip heterozygous mice (Hhip+/-) recapitulated multiple COPD pathological features including smoke- and age-related emphysema and airway remodeling. We also found that HHIP is highly expressed in Lgr6-expressing airway smooth muscle cells (ASMCs) and Lgr5- expressing alveolar mesenchymal cells; has reduced expression in COPD ASMCs that display a metabolic shift from oxidative phosphorylation to glycolysis associated with increased cell growth. Furthermore, alveolar fibroblasts-derived HHIP promotes proliferation of AT II (alveolar type II) cells in alveolar organoid co-culture model. These findings suggested that Hhip, the key genetic determinant for COPD, possibly modulates both airway remodeling and emphysema through complementarily intrinsic and extrinsic signaling in two major lung mesenchymal cell types: ASMCs and alveolar mesenchymal cells. In this current proposal, we aim to extend our previous studies by addressing two mechanistic questions related with HHIP: 1) How deficiency of Hhip in ASMCs promote airway remodeling by increasing airway thickening and cell hyperplasia through metabolic reprograming and 2) whether and how deficiency of Hhip in alveolar mesenchymal cells have impaired niche to support AT II cell generation. These questions will be addressed through the combinations of biochemical assays, lineage tracing, CRISPR-based genome editing and organoid co-culture models. In Aim1, we have identified a novel interaction between HHIP and PKM2 (pyruvate kinase isozyme M2), a rate-limiting enzyme in the last step for glycolysis. We will further characterize their interaction in AMSCs as well as determine impacts of HHIP on CS-induced airway remodeling. In Aim 2, we hypothesize that Hhip deficiency leads to impaired niche function in Lgr5+ alveolar mesenchymal cells that are important for AT II cells regeneration thereby determines emphysema susceptibility. To test this, we choose to conditionally deplete Hhip in Lgr5+ cells, a known alveolar mesenchymal cells marker followed by CS exposure and subsequent measurements on airspace size, the activity of the Wnt and Hedgehog pathway and proliferation and differentiation of both alveolar mesenchymal cells (Lgr5+) and AT II cells by complementary approaches in Aim 2.1. In Aim 2.2., we will use alveolar organoid co-culture model to dissect the mechanism by which Hhip determines niche function using either murine cells from Hhip deficient mice or from human primary fibroblasts edited by CRISPR/Cas-9 method targeting HHIP. Successful completion of this project will illuminate molecular insights into CS-induced COPD susceptibility determined by HHIP.
慢性阻塞性肺病(COPD)是美国第三大致死原因。它也是 受吸烟(CS)和遗传易感性的强烈影响。HHIP,编码刺猬交互 蛋白质一直与COPD的易感性有关,包括气道重塑和 肺气肿。然而,这种联系背后的分子机制仍然不完全。 明白了。我们发表的工作表明,HHIP杂合子小鼠(HHIP+/-)可概括为多个 COPD的病理特征包括吸烟和年龄相关的肺气肿和气道重塑。我们也 发现HHIP在表达Lgr6的气道平滑肌细胞(ASMC)和Lgr5高表达。 表达肺泡间充质细胞;在表现为代谢的COPD ASMCs中表达降低 随着细胞生长的增加,从氧化磷酸化转变为糖酵解。此外,肺泡 成纤维细胞来源的HHIP促进肺泡II型细胞增殖 模特。这些发现表明,慢性阻塞性肺疾病的关键基因决定因素HHIP可能调节两者 两大肺内、外信号互补的气道重塑与肺气肿 间充质细胞类型:间质细胞和肺泡间充质细胞。在目前的提案中,我们的目标是延长 我们以前的研究通过解决与髋关节相关的两个力学问题:1)髋关节如何在 ASMC通过代谢增加气道增厚和细胞增殖促进气道重塑 2)肺泡间充质细胞HHIP的缺失是否以及如何损害了 支持AT II细胞生成。这些问题将通过生物化学的组合来解决 分析、谱系追踪、基于CRISPR的基因组编辑和有机化合物共培养模型。在Aim1,我们有 发现了HHIP与PKM2(丙酮酸激酶同工酶M2)之间的一种新的相互作用,PKM2是HHIP的限速酶 糖酵解的最后一步。我们将进一步描述它们在AMSC中的相互作用,并确定其影响 HHIP对CS诱导的气道重塑的影响。在目标2中,我们假设髋关节缺陷会导致受损 Lgr5+肺泡间充质细胞的生态位功能对AT II细胞的再生非常重要 决定了肺气肿的易感性。为了测试这一点,我们选择有条件地耗尽Lgr5+细胞中的HHIP,a 已知的肺泡间充质细胞标记物和CS暴露后的后续测量 空域大小、Wnt和Hedgehog通路的活性以及两者的增殖和分化 肺泡间充质细胞(Lgr5+)和AT II细胞在Aim 2.1中的互补方法。在AIM 2.2中,我们 将使用肺泡有机化合物共培养模型来剖析HHIP决定生态位功能的机制 使用HHIP缺陷小鼠的小鼠细胞或CRISPR/Cas-9编辑的人原代成纤维细胞 方法靶向HHIP。该项目的成功完成将阐明对CS诱导的分子洞察力 HHIP法测定COPD易感性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wenyi Wei其他文献

Wenyi Wei的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wenyi Wei', 18)}}的其他基金

Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies
破译泛素化和磷酸化途径之间的生理作用和相互作用,以指导靶向癌症治疗
  • 批准号:
    10240580
  • 财政年份:
    2020
  • 资助金额:
    $ 65.55万
  • 项目类别:
Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies
破译泛素化和磷酸化途径之间的生理作用和相互作用,以指导靶向癌症治疗
  • 批准号:
    10663923
  • 财政年份:
    2020
  • 资助金额:
    $ 65.55万
  • 项目类别:
Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies
破译泛素化和磷酸化途径之间的生理作用和相互作用,以指导靶向癌症治疗
  • 批准号:
    10456316
  • 财政年份:
    2020
  • 资助金额:
    $ 65.55万
  • 项目类别:
Integrative Characterization on the function of COPD GWAS gene, HHIP
COPD GWAS 基因 HHIP 功能的综合表征
  • 批准号:
    9886349
  • 财政年份:
    2020
  • 资助金额:
    $ 65.55万
  • 项目类别:
Integrative Characterization on the function of COPD GWAS gene, HHIP
COPD GWAS 基因 HHIP 功能的综合表征
  • 批准号:
    10598541
  • 财政年份:
    2020
  • 资助金额:
    $ 65.55万
  • 项目类别:
Targeting the APC/Cdc20 E3 ubiquitin ligase for chemoradiation sensitization
靶向 APC/Cdc20 E3 泛素连接酶进行放化疗增敏
  • 批准号:
    9285774
  • 财政年份:
    2016
  • 资助金额:
    $ 65.55万
  • 项目类别:
Characterizing the signaling pathways that regulate Skp2 oncogenic function
表征调节 Skp2 致癌功能的信号通路
  • 批准号:
    9172846
  • 财政年份:
    2016
  • 资助金额:
    $ 65.55万
  • 项目类别:
Targeting the APC/Cdc20 E3 ubiquitin ligase for chemoradiation sensitization
靶向 APC/Cdc20 E3 泛素连接酶进行放化疗增敏
  • 批准号:
    9922891
  • 财政年份:
    2016
  • 资助金额:
    $ 65.55万
  • 项目类别:
Characterizing the signaling pathways that regulate Skp2 oncogenic function
表征调节 Skp2 致癌功能的信号通路
  • 批准号:
    9918851
  • 财政年份:
    2016
  • 资助金额:
    $ 65.55万
  • 项目类别:
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies
PI3K/Akt 的新调控可指导乳腺癌靶向治疗
  • 批准号:
    10577734
  • 财政年份:
    2013
  • 资助金额:
    $ 65.55万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 65.55万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 65.55万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.55万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.55万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 65.55万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.55万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 65.55万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 65.55万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 65.55万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.55万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了